Olema Pharmaceuticals, Inc. announced interim results from an ongoing Phase 1b/2 clinical study of palazestrant (OP-1250) in combination with CDK4/6 inhibitor ribociclib, a Poster Spotlight Session on interim Phase 2 clinical data of palazestrant in combination with palbociclib, and a trials-in-progress poster for the OPERA-01 monotherapy Phase 3 pivotal trial at the San Antonio Breast Cancer Symposium (SABCS) at the Henry B. Gonzalez Convention Center in San Antonio, Texas. These full data are scheduled to be presented on December 7, 2023, and copy of the posters are available now on Olema's website under the Science section. Palazestrant Phase 1b/2 Study in Combination with Ribociclib: A poster titled "A Phase 1b/2 study of palazestrant ("A Phase 1b/2" study of palazestrant(OP-1250) in combined with ribociclib in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative, advanced and/or metastatic breast cancer" will be presented at SABCS.

A more recent data cut, as of November 1, 2023, highlights the following: Across 19 patients who had completed at least one cycle of treatment as of the data cutoff date, the combination of up to 120 mg of palazestrant with 600 mg of ribociclib daily was well tolerated, with no safety signals or enhancement of toxicity and an overall safety profile remains consistent with the expected safety profile of ribociclib plus an endocrine therapy. OPERA-01 Phase 3 Monotherapy Trial: Olema will present a poster titled "OPERA-01: A randomized, open-label, phase 3, study of palazestrant®? vs standard-of-care treatment for ER+, HER2- advanced or metastatic breast cancer after endocrine and CDK4/6 inhibitor therapy", that detailed the ongoing clinical trial design, inclusion/exclusion criteria, and trial endpoints.